Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-011)

Trial Profile

A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-011)

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2019

At a glance

  • Drugs Tildrakizumab (Primary) ; Etanercept
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms reSURFACE 2
  • Sponsors Sun Pharma Global FZE
  • Most Recent Events

    • 19 Jun 2019 Results of a pooled analysis of reSURFACE 1 and reSURFACE 2 trials assessing the long-term efficacy and safety of tildrakizumab treatment for moderate-to-severe psoriasis for up to 148 weeks, published in the British Journal of Dermatology
    • 22 May 2019 Results assessing prediction of week-28 PASI response status by using data from two phase III studies (reSURFACE 1 and reSURFACE 2) presented at the 24th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 17 Apr 2019 According to an Almirall S.A. media release, the NICE (National Institute for Health and Care Excellence, in the UK) has has recommended Tildrakizumab as a cost effective treatment option for the NHS for the patients specified in the Final Appraisal Determination (FAD).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top